Bain Capital Life Sciences Investors, LLC — SEC Form 4 filings
SEC reporting owner CIK 1703031. 10 Form 4 filings on record with FilingPulse; latest filed 2026-05-22.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-01-12 to 2026-05-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 4 filings — 3,312,500 shares, $40,657,370 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 2 filings — 4,000,000 shares, $114,998,336 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 2,000,000 shares @ $28.05 ($56,100,000) in Heartflow, Inc., filed 2026-02-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Heartflow, Inc. (HTFL) | 10% owner | 3 | — | 5 legs · 4,000,000 sh · $114,998,336 | 4 |
| Kailera Therapeutics, Inc. (KLRA) | 10% owner | 1 | 1 leg · 1,562,500 sh · $25,000,000 | — | 4 |
| Kyverna Therapeutics, Inc. (KYTX) | 10% owner | 1 | 1 leg · 450,000 sh · $9,900,000 | — | 2 |
| Solid Biosciences Inc. (SLDB) | 10% owner | 2 | 1 leg · 1,000,000 sh · $4,030,000 | — | 2 |
| Olema Pharmaceuticals, Inc. (OLMA) | 10% owner | 1 | 1 leg · 300,000 sh · $1,727,370 | — | 2 |
| RAPID MICRO BIOSYSTEMS, INC. (RPID) | 10% owner | 1 | — | — | 3 |
| NewAmsterdam Pharma Co N.V. (NAMS) | 10% owner | 1 | — | — | 1 |
Form 4 filings — Bain Capital Life Sciences Investors, LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-22 | 4 | RAPID MICRO BIOSYSTEMS, INC. (RPID) jointly with Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP | Purchase (P): 1,463,000 (derivative) · Purchase (P): 1,463,000 (derivative) · Purchase (P): 1,463,000 (derivative) | EDGAR |
| 2026-04-30 | 4 | Heartflow, Inc. (HTFL) jointly with Bain Capital Life Sciences III General Partner, LLC, Bain Capital Life Sciences Fund III, L.P., BCLS Fund III Investments GP, LLC, BCLS Fund III Investments, LP | Sale (S): 254,110 @ $30.51 · Sale (S): 797,133 @ $29.37 · Sale (S): 892,533 @ $29.18 · Sale (S): 56,224 @ $30.05 | EDGAR |
| 2026-04-20 | 4 | Kailera Therapeutics, Inc. (KLRA) jointly with Bain Capital Life Sciences IV General Partner, LLC, Bain Capital Life Sciences Fund IV, L.P., BCLS Fund IV Investments GP, LLC, BCLS Fund IV Investments, L.P. | Conversion (C): 16,875,000 · Conversion (C): 4,145,768 · Purchase (P): 1,562,500 @ $16 · Conversion (C): 16,875,000 (derivative) @ $0 · Conversion (C): 4,145,768 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Heartflow, Inc. (HTFL) jointly with Bain Capital Life Sciences III General Partner, LLC, Bain Capital Life Sciences Fund III, L.P., BCLS Fund III Investments GP, LLC, BCLS Fund III Investments, LP | Sale (S): 2,000,000 @ $28.05 | EDGAR |
| 2025-08-13 | 4 | Heartflow, Inc. (HTFL) jointly with Bain Capital Life Sciences III General Partner, LLC, Bain Capital Life Sciences Fund III, L.P., BCLS Fund III Investments GP, LLC, BCLS Fund III Investments, LP | Conversion (C): 12,014,234 · Conversion (C): 433,924 @ $15.20 · Conversion (C): 35,081,564 (derivative) @ $0 · Conversion (C) @ $0 | EDGAR |
| 2025-02-21 | 4 | Solid Biosciences Inc. (SLDB) jointly with BCLS SB Investco, LP, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund II, L.P., Bain Capital Life Sciences Investors II, LLC, BCLS II Investco, LP, BCLS II Investco (GP), LLC, BCIP Life Sciences Associates, LP, BCLS II Equity Opportunities, LP, BCLS II Equity Opportunities GP, LLC | Purchase (P): 1,000,000 @ $4.03 · Purchase (P): 6,444,170 (derivative) @ $4.03 | EDGAR |
| 2025-01-13 | 4 | Olema Pharmaceuticals, Inc. (OLMA) jointly with Bain Capital Life Sciences IV General Partner, LLC, Bain Capital Life Sciences Fund IV, L.P., Bain Capital Life Sciences Opportunities IV GP, LLC, Bain Capital Life Sciences Opportunities IV, L.P. | Purchase (P): 300,000 @ $5.76 · Other (J): 3,500,000 · Other (J): 3,500,000 (derivative) | EDGAR |
| 2024-12-17 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) jointly with BCLS Fund III Investments, LP, Bain Capital Life Sciences III General Partner, LLC, Bain Capital Life Sciences Fund III, L.P., BCLS Fund III Investments GP, LLC, BCLS II Investco, LP, BCLS II Investco (GP), LLC, Bain Capital Life Sciences Fund II, L.P., Bain Capital Life Sciences Investors II, LLC, BCIP Life Sciences Associates, LP | Purchase (P): 1,632,653 (derivative) @ $24.50 | EDGAR |
| 2024-02-14 | 4 | Kyverna Therapeutics, Inc. (KYTX) jointly with Bain Capital Life Sciences III General Partner, LLC, Bain Capital Life Sciences Fund III, L.P., Bain Capital Life Sciences Opportunities III GP, LLC, Bain Capital Life Sciences Opportunities III, LP | Conversion (C): 2,713,868 · Purchase (P): 450,000 @ $22 · Conversion (C): 12,351,087 (derivative) @ $0 | EDGAR |
| 2024-01-12 | 4 | Solid Biosciences Inc. (SLDB) jointly with BCLS SB Investco, LP, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund II, L.P., Bain Capital Life Sciences Investors II, LLC, BCLS II Investco, LP, BCLS II Investco (GP), LLC, BCIP Life Sciences Associates, LP | Grant/award (A): 904,160 @ $5.53 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1703031 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →